Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Short-term Investments (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Short-term Investments for 6 consecutive years, with $38.7 million as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Short-term Investments fell 53.24% year-over-year to $38.7 million, compared with a TTM value of $38.7 million through Sep 2019, down 53.24%, and an annual FY2018 reading of $68.7 million, up 12.17% over the prior year.
  • Short-term Investments was $38.7 million for Q3 2019 at Larimar Therapeutics, down from $54.4 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $165.2 million in Q3 2015 and bottomed at $35.1 million in Q2 2018.
  • Average Short-term Investments over 5 years is $87.0 million, with a median of $74.3 million recorded in 2017.
  • The sharpest move saw Short-term Investments soared 160.61% in 2015, then tumbled 53.24% in 2019.
  • Year by year, Short-term Investments stood at $149.5 million in 2015, then tumbled by 35.22% to $96.8 million in 2016, then tumbled by 36.73% to $61.3 million in 2017, then increased by 12.17% to $68.7 million in 2018, then plummeted by 43.74% to $38.7 million in 2019.
  • Business Quant data shows Short-term Investments for LRMR at $38.7 million in Q3 2019, $54.4 million in Q2 2019, and $68.2 million in Q1 2019.